| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b7e87f29e0db9416800cab4f60f6c468 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21 |
| filingDate |
2012-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c4cf38303442c04f7df243651f5abd6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46469e581fa756432877748b0d6ad492
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e6c5d82a04e173f418189241a92cb5f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1fbb3d65ddd38e5f0d1418192aea185 |
| publicationDate |
2014-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
MX-2014007681-A |
| titleOfInvention |
NEW ANTIHUMAN CTGF ANTIBODY. |
| abstract |
{Problem} Provide: an anti-human CTGF antibody that has superior binding activity and / or superior neutralizing activity compared to that of conventional anti-human CTGF antibodies; and a means to prevent or treat various diseases in which human CTGF is involved in the formation of clinical conditions thereof, which includes renal diseases such as chronic kidney disease and diabetic nephropathy, by using the aforementioned anti-human CTGF antibody. {Solution} An anti-human CTGF antibody containing a heavy chain variable region comprising the amino acid sequence represented by SEQ ID NO: 10 and a light chain variable region comprising the amino acid sequence represented by SEQ ID NO: 4. |
| priorityDate |
2011-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |